Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

61. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care

Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised (...) with irritable bowel syndrome (IBS). The authors concluded that acupuncture was not cost-effective for all patients, but it might be for a subgroup of patients with more severe disease. The methods and data used for the analysis were clearly reported and appropriate. The authors' conclusion appears to be appropriate. Type of economic evaluation Cost-utility analysis Study objective This study evaluated the cost-effectiveness of acupuncture for patients with irritable bowel syndrome (IBS). Interventions

NHS Economic Evaluation Database.2012

62. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis Menees SB, Maneerattannaporn M, Kim HM, Chey WD CRD summary The authors concluded that treatment with rifaximin was more effective than placebo for global symptoms (...) and bloating in patients with irritable bowel syndrome. The modest therapeutic gain was similar to that of other therapies. The authors' conclusion for short-term treatment compared with placebo reflects the evidence presented and seems reliable; the comparison with other treatments is not substantiated. Authors' objectives To evaluate the efficacy and tolerability of rifaximin in patients with irritable bowel syndrome (IBS). Searching PubMed, EMBASE, The Cochrane Library and Web of Science were searched up

DARE.2012

63. Systematic review with meta-analysis: In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents

Systematic review with meta-analysis: In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents | Evidence-Based Medicine This site uses cookies. By continuing to browse (...) the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain

Evidence-Based Medicine (Requires free registration)2012

64. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation 20801122 2010 12 03 2011 01 04 2010 12 03 1528-0012 139 6 2010 Dec Gastroenterology Gastroenterology Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. 1877-1886.e2 10.1053/j.gastro.2010.08.041 Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C (...) , has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C. We performed a randomized, double-blind, multicenter, placebo-controlled study of 420 patients with IBS-C given oral linaclotide at doses of 75, 150, 300, or 600 μg or placebo once daily for 12 weeks. End points included change from baseline in daily bowel habits

EvidenceUpdates2011

65. Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Rifaximin therapy for patients with irritable bowel syndrome without constipation. 21208106 2011 01 06 2011 01 12 2015 06 24 1533-4406 364 1 2011 Jan 06 The New England journal of medicine N. Engl. J. Med. Rifaximin therapy for patients with irritable bowel syndrome without constipation. 22-32 10.1056/NEJMoa1004409 Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic (...) , as treatment for IBS. In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS

NEJM2011

66. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis 20691689 2010 11 01 2010 11 30 2016 12 15 1528-0012 139 5 2010 Nov Gastroenterology Gastroenterology Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. 1549-58, 1558.e1 10.1053/j.gastro.2010.07.052 Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (...) (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C). In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations of placebo, 500 mg CDC, or 1000 mg CDC for 4 days. We assessed gastrointestinal and colonic transit, stool characteristics, and associations of transit with fasting serum 7αC4 (surrogate of bile acid synthesis) and FGF19 (negative regulator

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

67. A randomized, double-blind, placebo-controlled trial of St John`s wort for treating irritable bowel syndrome

A randomized, double-blind, placebo-controlled trial of St John`s wort for treating irritable bowel syndrome 19809408 2010 01 07 2010 02 25 2010 11 04 1572-0241 105 1 2010 Jan The American journal of gastroenterology Am. J. Gastroenterol. A randomized, double-blind, placebo-controlled trial of St John's wort for treating irritable bowel syndrome. 170-7 10.1038/ajg.2009.577 St John's wort (SJW) is known to effectively treat patients with mild-to-moderate depression. Antidepressants (...) are frequently used to treat irritable bowel syndrome (IBS). To date, no study that examines the efficacy of SJW in IBS has been carried out. The aim of this study was to evaluate the efficacy of SJW in IBS after 12 weeks. In this randomized, double-blind, placebo-controlled trial, 70 participants with an established diagnosis of IBS were randomized and assigned by concealed allocation to either SJW or placebo. Both treatment arms were balanced on symptom subtype. The primary end point was self-reported

EvidenceUpdates2010

68. Systematic review: self-management support interventions for irritable bowel syndrome

Systematic review: self-management support interventions for irritable bowel syndrome Systematic review: self-management support interventions for irritable bowel syndrome Systematic review: self-management support interventions for irritable bowel syndrome Dorn SD CRD summary The review concluded that many self-management support interventions appeared to benefit irritable bowel syndrome patients, although the flawed data and feasibility of interventions in clinical practice limited (...) the results; further research is needed. The author's conclusions were suitably cautious and reflect the evidence, but the review had some methodological problems, which should be borne in mind. Authors' objectives To assess the self-management interventions used to support irritable bowel syndrome patients. Searching PubMed, EMBASE, PsycINFO, and CINAHL were searched to March 2010 for articles published in any language. Search terms were reported. Reference lists of retrieved articles were also searched

DARE.2010

69. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome Darvish-Damavandi M, Nikfar S, Abdollahi M CRD summary The review concluded that mebeverine did not significantly improve the global symptoms of irritable bowel syndrome or relieve the associated abdominal pain (...) , but it was mostly well tolerated, with no significant adverse events. Although the included trials were of high quality, the evidence was limited, so the reliability of the authors' conclusions is unclear. Authors' objectives To evaluate the safety and efficacy of mebeverine for irritable bowel syndrome. Searching PubMed, EMBASE, Scopus, and the Cochrane Library were searched up to June 2009 for publications in any language; search terms were reported. Google was also searched. Bibliographies of each retrieved

DARE.2010

70. [Burden of irritable bowel syndrome in Korea]

[Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park HJ, Lee PL, Lee JS, Lee KJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park (...) HJ, Lee PL, Lee JS, Lee KJ. [Burden of irritable bowel syndrome in Korea] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-09-018, NECA-A-10-007. 2010 Authors' conclusions During a single year of 2008, the prevalence of IBS was 5.1% in males and 6.9% in females, yielding a female/male ratio of 1.44. According to the survey, the estimation of patients' quality of life by using the EQ-5D tool resulted in a score of 0.889 that was lower than the score (EQ-5D index

Health Technology Assessment (HTA) Database.2010

71. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis Rezaie A, Nikfar S, Abdollahi M CRD summary The review found that antibiotics had some beneficial effects in irritable bowel syndrome patients, especially with bloating (...) as the predominant symptom, but could not be recommended because of lack of available evidence; further research is needed. The authors' cautious conclusions are appropriate and reflect the lack of available evidence. Authors' objectives To assess the efficacy of intestinal bacterial eradication with antibiotic therapy in adults with irritable bowel syndrome and irritable bowel syndrome-type symptoms. Searching PubMed, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) were

DARE.2010

72. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM CRD summary This review concluded that probiotics appeared to be efficacious in the treatment of irritable bowel syndrome (...) , but that the magnitude of benefit and the most effective probiotic species and strain remained uncertain. The review was generally well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of probiotics in the treatment of irritable bowel syndrome. Searching The following databases were searched, with no language restrictions, from inception to June 2008: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Search terms were reported

DARE.2010

73. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions

Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions 19690523 2009 12 03 2010 01 26 2016 11 22 1572-0241 104 12 2009 Dec The American journal of gastroenterology Am. J. Gastroenterol. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions. 3004-14 10.1038/ajg.2009.479 Psychological and behavioral therapies are being increasingly used (...) for symptom management in patients with irritable bowel syndrome (IBS). The aims of this study were to compare two delivery modes for a comprehensive self-management (CSM) intervention, primarily by telephone vs. entirely in person, and to compare each with usual care (UC). Adults with IBS were recruited through community advertisement. Subjects (N=188) were randomly assigned to three groups: one in which all nine weekly CSM sessions were delivered in person, one in which six of the nine sessions were

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro

74. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study 19438846 2009 07 23 2010 02 22 2015 11 19 1365-2036 30 3 2009 Aug Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. 245-52 10.1111/j.1365-2036.2009.04041.x Intestinal immune infiltration contributes to symptoms in patients (...) with irritable bowel syndrome (IBS). To assesses the effect of mesalazine (mesalamine) on mucosal immune cells in patients with IBS, through a pilot study. A randomized, double-blind, placebo-controlled trial in 20 patients with IBS in tertiary care setting. Patients were randomized to receive placebo or 800 mg mesalazine three times daily for 8 weeks. The primary endpoint was a significant reduction in total colonic immune cells on biopsies obtained at the end of treatment compared to baseline. Secondary

EvidenceUpdates2009

75. Psychological treatments for the management of irritable bowel syndrome.

Psychological treatments for the management of irritable bowel syndrome. BACKGROUND: No consensus exists on the optimal treatment for irritable bowel syndrome (IBS). Psychological treatments are increasingly advocated but their effectiveness is unclear. OBJECTIVES: To evaluate the efficacy of psychological interventions for the treatment of irritable bowel syndrome. SEARCH STRATEGY: A computer assisted search of MEDLINE, EMBASE, PsychInfo, CINAHL, Web of Science, The Cochrane Library and Google (...) was significantly limited by issues of validity, heterogeneity, small sample size and outcome definition. Future research should adhere to current recommendations for IBS treatment trials and should focus on the long-term effects of treatment.

Cochrane2009

76. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. BACKGROUND: Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. It is unclear whether the diagnosis includes children with different aetiologies for their pain. For the majority no organic cause for their pain can be found on physical examination or investigation. Although most children are likely (...) searched . Where appropriate, search filters were employed. Researchers working in this area were asked to identify relevant studies. SELECTION CRITERIA: Randomised or quasi-randomised studies of any dietary treatment versus placebo or no treatment in school-age children with a diagnosis of RAP or functional gastrointestinal disorder based on the Rome II criteria. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trials for inclusion, assessed quality and extracted data. Where

Cochrane2009

77. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Jellema P, van der Windt DA, Schellevis FG, van der Horst HE CRD summary This review concluded that organic disease could not be accurately excluded by symptom (...) -based irritable bowel syndrome criteria alone. The review was generally well conducted, but the possibility of missed studies means that these conclusions should be interpreted with some caution. Authors' objectives To determine the accuracy of symptom-based irritable bowel syndrome (IBS) criteria in excluding organic disease and individual signs and symptoms in diagnosing IBS. Searching PubMed and EMBASE were searched to September 2008. Some details of the search were provided and included

DARE.2009

78. Psychological treatments may be effective for managing irritable bowel syndrome

Psychological treatments may be effective for managing irritable bowel syndrome PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Psychological treatments may be effective for managing irritable bowel syndrome Clinical question How effective are psychological interventions for the treatment of irritable bowel syndrome (IBS)? Bottom line Psychological interventions (cognitive (...) of the included studies, variability in outcome definitions and small sample sizes which resulted in considerable heterogeneity. Context IBS is a chronic functional gastrointestinal disorder, with an estimated prevalence in Europe of up to 24% in women and 19% in men.1 No consensus exists on the optimal treatment for IBS. Psychological treatments are increasingly advocated but their effectiveness is unclear. Cochrane Systematic Review Zildenbos IL et al. Psychological treatments for the management

Cochrane PEARLS2009

79. Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome

Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndromeCommentary | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndromeCommentary Article Text Therapeutics Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome Commentary Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2009

80. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P CRD summary The authors concluded that alosetron, cilansetron and tegaserod (drugs acting (...) on 5-hydroxytryptamine receptors) were all effective in irritable bowel syndrome; serious adverse events were rare in trials included in this review. This was generally a well-conducted review and the authors’ conclusions are likely to be reliable. Authors' objectives To evaluate the effectiveness of 5-hydroxytryptamine 3 (5-HT 3 ) antagonists and 5-hydroxytryptamine 4 (5-HT 4 ) agonists in adults with irritable bowel syndrome (IBS). Searching MEDLINE (from 1950), EMBASE (from 1980

DARE.2009